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In cells, DNA repair has to keep up with DNA damage to maintain the integrity of the genome and prevent mutagenesis and
carcinogenesis. While the importance of both DNA damage and repair is clear, the impact of imbalances between both processes
has not been studied. In this paper, we created a combined mathematical model for the formation of DNA adducts from oxidative
estrogenmetabolismfollowedbybaseexcisionrepair(BER)oftheseadducts.Themodelencompassesasetofdiﬀerentialequations
representing the sequence of enzymatic reactions in both damage and repair pathways. By combining both pathways, we can
simulate the overall process by starting from a given time-dependent concentration of 17β-estradiol (E2) and 2 -deoxyguanosine,
determine the extent of adduct formation and the correction by BER required to preserve the integrity of DNA. The model allows
us to examine the eﬀect of phenotypic and genotypic factors such as diﬀerent concentrations of estrogen and variant enzyme
haplotypes on the formation and repair of DNA adducts.
1.Introduction
Estrogens are known carcinogens recognized as prime risk
factorforthedevelopmentofbreastcancer[1].Theprincipal
enzyme controlling estrogen metabolism in breast tissue is
cytochromeP4501B1(CYP1B1),whichsequentiallyoxidizes
E2 to4-OHE2 andtheestrogenquinone(E2-3,4-Q,Figure 1).
The highly reactive quinone nonenzymatically attacks DNA
and forms covalent adducts with bases, such as 4-OHE2-N7-
Gua (GUAadduct), which undergoes depurination by hydrol-
ysis of the N-glycosylic bond between base and sugar, leaving
an apurinic (AP) site in the double-stranded DNA. AP sites
are repaired by the base excision repair (BER) pathway in
a sequence of enzymatic reactions. AP endonuclease APE1
cleaves 5  to the AP site to generate a nick with 3 -OH and
5 -deoxyribose phosphate termini. DNA polymerase (Pol)
catalyzes the release of the deoxyribose phosphate residue
and DNA synthesis to ﬁll the gap, which is then sealed by
DNA ligase (Figure 1). This reaction sequence is carried out
in one of two pathways, “short-patch” and “long-patch”,
which diﬀer in the number of inserted nucleotides and the
protein components.
In this paper, we present a mathematical model for
the formation of DNA adducts from oxidative estrogen
metabolism followed by BER of these adducts. The modeling
is initially done in two stages: (1) formation of estrogen-
deoxyribonucleoside adducts, and (2) repair of adducts in
the BER. By combining both stages, we can simulate the
overall process by starting from a given time-dependent
concentration of E2 and 2 -deoxyguanosine, determine the
extent of adduct formation and the correction by BER
required to preserve the integrity of DNA.
2. Mathematical Model
The mathematical model is constructed in stages. Stage 1
deals with the formation of DNA adducts from estrogen
metabolism and Stage 2 encompasses the repair of adducts.
In the diﬀerential equations that will constitute the model,
E2 denotes 17β-estradiol, 4-OHE2 the catechol estrogen, E2-
3,4-Q the estrogen quinone, GUA the deoxyribonucleoside
2 -deoxyguanosine, and GUAadduct the estrogen adduct 4-
OHE2-N7-Gua over time t. We assume that the starting2 Journal of Nucleic Acids
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Figure 1: Overview of estrogen metabolism-induced DNA adduct formation and subsequent DNA repair by BER. The top sequence of
reactions shows the CYP1B1-mediated oxidative estrogen metabolism resulting in estrogen-deoxyribonucleoside adduct formation. The
bottom sequence of reactions shows the BER pathway with its two branches, the predominant short-patch pathway (left) and the alternate
long-patch pathway (right). Not shown is the formation of the catechol estrogen 2-OHE2, which yields stable adducts, and the redox cycling
of catechol estrogens and estrogen quinones, which generates reactive oxygen species capable of producing oxidative DNA adducts.Journal of Nucleic Acids 3
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Figure 2: Comparison of stage 1 mathematical model (DNA damage) with experimental data. The metabolism of E2 (a), 4-OHE2 (b), and
GUAadduct (c) is shown as a function of time. In each graph the dots represent the experimental data [2], and the curves are derived from the
mathematical model.
points for the dynamic model are the initial concentration
of GUA(0) = GUA0 and a prescribed time series is given for
E2.
The ﬁrst stage of the model is based on the ﬁrst three
stepsofthereactionsequenceshowninFigure 1.Aschemical
reactions, these steps are
E2 +E CYP1B1  4-OHE2 +E CYP1B1,
4-OHE2 −→ E2-3,4-Q,
GU A+E 2-3,4-Q −→ GUAadduct.
(1)
In the ﬁrst reaction, the production of 4-OHE2 from E2
is an enzymatic reaction mediated by CYP1B1 that follows
Michaelis-MentenkineticswithparametersKm1 andkcat1 [3].
In the second reaction, E2-3,4-Q is produced from 4-OHE2
according to Hill-type kinetics. It has been shown that E2-
3,4-Q is highly reactive and will spontaneously form adducts
with DNA without enzyme involvement [2]. Thus, in the
third reaction, the formation of adducts is proportional to
the levels of the quinone and the deoxyribonucleoside with
a rate constant denoted by kQ. Estrogen-DNA adducts have
been detected in normal and malignant human breast tissues
[4, 5], and we have recently provided direct experimental
evidence that oxidative metabolism of the parent hormone
E2 leads to the formation of 4-OHE2 and deoxyribonu-
cleoside adducts, such as 4-OHE2-N7-Gua [2]. Using a
compartmental analysis we created a mathematical model
for reaction sequence (1). Figure 2 shows superimposed the
experimental data (dots) and the model simulations (curves)
for E2, 4-OHE2,a n dG U A adduct.
The second stage of the model is based on the BER
pathway (Figure 1) and uses a compartmental analysis
with Michaelis-Menten kinetics to simulate the enzymatic
reactions in the pathway [6]. The enzymes include the
endonucleases APE1 and FEN1, DNA polymerases β and δ
(Polβ,P o l δ), and ligases 1 and 3 (Lig1, Lig3). The dynamic
process is modeled by a system of nonlinear diﬀerential
equations. S(t) denotes the concentration of DNA adducts.
We deﬁne the source and removal function for the repair
cycle functions, S(t)a n dR(t), as S(t) = ksGUAadduct and
R(t) = kr(E2-3,4-Q)y9.H e r e ,ks is a modeling parameter
expressed in [1/min] which reﬂects the rate at which
GUAadduct enters the repair cycle. The parameter kr is
the rate at which y9(t) interacts with E2-3, 4-Q to form
GUAadduct. The two parameters, ks and kr,c a nb eu s e dt o
control the rates of entering and exiting of adducts and4 Journal of Nucleic Acids
Table 1: Parameters for System of Diﬀerential Equations [6].
Reaction subscript (i) kcati [1/min] Kmi [nmol/L]
5 192.168 34.7
6 4.500 500
7 49.020 210
8,11 1.278 56.7
9 36.000 100
10 8.130 39
repaired lesions, respectively. For the simulations, we have
chosen, kr = ks = 1,
dy4
dt
= S(t) −
kcat5EAPE1y4
Km5 + y2
,
dy5
dt
=
kcat5EAPE1y4
Km5 + y4
−
kcat6EPolβy5
Km6 + y5
−
kcat9EPolδy5
Km9 + y5
,
dy6
dt
=
kcat7EPolβy7
Km7 + y7
−
kcat6EPolβy6
Km6 + y6
,
dy7
dt
=
kcat6EPolβy5
Km6 + y5
−
kcat7EPolβy7
Km7 + y7
,
dy8
dt
=
kcat6EPolβy6
Km6 + y6
−
kcat11ELig1y8
Km11 + y8
−
kcat8ELig3y8
Km8 + y8
,
dy9
dt
=
kcat11ELig1y11
Km11 + y11
+
kcat8ELig3y11
Km8 + y11
+
kcat11ELig1y8
Km11 + y8
+
kcat8ELig3y8
Km8 + y8
− R(t),
dy10
dt
=
kcat9EPolδy5
Km9 + y5
−
kcat10EFEN1y10
Km10 + y10
,
dy11
dt
=
kcat10EFEN1y10
Km10 + y10
−
kcat11ELig1y11
Km11 + y11
−
kcat8ELig3y11
Km8 + y11
.
(2)
There are several Michaelis-Menten parameters, kcati and
Kmi,f o rw h i c he x p e r i m e n t a lv a l u e sh a v eb e e ne s t i m a t e d
or measured (Table 1)[ 6] .T h ee n z y m el e v e l sa r ed e n o t e d
by EAPE1,E FEN1,E Polβ,E Polδ,E Lig1,a n dE Lig3. The variable,
y9(t), represents the repaired GUAadduct, and if we set its
initial condition in the system of diﬀerential equations as
y9(0) = GUA0, it has the same meaning as GUA(t).
AP endonucleases, such as AP endonuclease 1 (APE1), are
quite abundant in most cells, ranging from 200,000 to
7,000,000 APE1 molecules per cell in ﬁbroblasts and HeLa
cells, respectively [7, 8]. Thus, the minimal concentration
of APE1 in nuclear extract can be assumed to be 2000nM
[6]. The equivalent estimated concentrations of Polβ,P o l δ,
FEN1, Lig1, and Lig3 are 419, 600, 450, 254, and 254nM,
respectively [6, 9, 10].
It is estimated that AP sites are also generated sponta-
neously at an estimated rate of 2,000 to 10,000 per cell per
day [11, 12]. We used (2) to determine the time necessary
to repair these AP sites. In Figure 3 we demonstrate that the
repair of lesions is a nonlinear process. For small values of
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Figure 3: Stage 2 mathematical model of BER. The plot shows
the time required to repair a ﬁxed number of AP sites per 105
nucleotides with wild-type BER enzymes. The horizontal axis
represents the starting number of AP sites per 105 nucleotides and
the vertical axis the time for this number of sites to be repaired.
theratio(AP lesions/105 Nucleotides),theslopeoftherepair
time function is relatively large as compared to larger values
of the ratio. Figure 3 captures the dynamics of only the repair
part of the model, that is, it shows the repair times for a ﬁxed
amount of AP lesions.
In the experiments addressed mathematically in Stage
1 of the model, we demonstrated that the CYP1B1-
mediated oxidation of E2 resulted in the formation of
approximately 10nmol/L 4-OHE2-N7-Gua, which translates
into 10 adducts per 105 nucleotides per hour [2]. Since
the formation of 4-OHE2-N7-Gua leads to spontaneous
depurination [13], we can assume an equal number of AP
sites formed as a result of oxidative estrogen metabolism.
This is one order of magnitude higher than the number
of AP sites formed in normal leukocytes and ﬁbroblasts,
10AP sites per 106 nucleotides per hour [13]. The living
cell depends on eﬃcient enzymatic repair of the continuous
chemical damage inﬂicted on genomic DNA. Therefore, in
the last stage of the model we combine the adduct formation
model (Stage 1) and the adduct repair model (Stage 2). The
mathematical model used in Stage 1 was chosen to ﬁt batch
data (a ﬁxed amount of E2). However, we consider the case
whenE2 iscontinuouslyavailableandcanvaryovertimeand
hence, there is continuous adduct formation and repair. In
our modiﬁcation of the Stage 1 model, we assume that the
t o t a la m o u n to f2  -deoxyguanosine is ﬁxed, and it exists in
twostates:damaged(GUAadduct)andundamagedorrepaired
(y9). The modiﬁed Stage 1 model, which accounts for the
continuous nature of damage and repair, is then given by the
following system of ordinary diﬀerential equations
d(4-OHE2)
dt
=
kcat1ECYP1B1E2
Km1 +E 2
−
VmaxQ4-OHE2
KmQ +4-OHE2
,
d(E2-3,4-Q)
dt
=
VmaxQ4-OHE2
KmQ +4-OHE2
− kQE2-3,4-Q,
d(GUAadduct)
dt
= kr(E2-3,4-Q)y7 −ksGUAadduct.
(3)Journal of Nucleic Acids 5
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Figure 4: Eﬀects of diﬀerent concentrations of estrogen and variant haplotypes of CYP1B1 and APE1 on the formation and repair of DNA
adducts. (a) Shows the eﬀect of doubling the concentration of E2 on the number of AP lesions per 105 nucleotides over time using E2 = 1
(red curve) and E2 = 2 (blue curve). (b) Shows the eﬀect of variant haplotypes of CYP1B1 and APE1 leading to an increase in the number
of AP lesions per 105 nucleotides relative to wild-type enzymes. Each curve uses diﬀerent assumptions about the kinetic constant, kcat,f o r
the CYP1B1 and APE1 enzymes. The red curve depicts the wild-types with kcat1 = 1.6( C Y P 1 B 1 )a n dkcat5 = 192.168 (APE1). The blue curve
uses a 30% increase in kcat1, keeping kcat5 = 192.168. The green curve employs a 30% reduction in kcat1, keeping kcat5 = 192.168. Finally, the
purple curve uses both a 30% increase in kcat1 and a 30% reduction in kcat5. (c) Shows the eﬀe c to fd i ﬀerent variant haplotypes of CYP1B1
and APE1 that cause a decrease in the number of AP lesions per 105 nucleotides relative to wild-type enzymes. The wild-type is shown in
red, a 30% decrease of CYP1B1 activity with APE1 activity held at its wild-type level in blue, 30% increase of APE1 activity with CYP1B1
activity held at its wild-type level in green, and a 30% decrease in CYP1B1 activity with a 30% increase of APE1 activity in purple.
The endpoint of the repair process is y9(t) which is the
concentration of GUA(t). The term, R(t) = kry9(E2-3,4-Q)
where kr is a constant, is the term that connects (2)a n d
(3). In case the AP sites are not generated spontaneously but
produced by DNA glycosylases, we can easily incorporate the
enzymatic reaction catalyzed by glycosylases, which is not
rate limiting for BER [9].
The combined Stage 3 model is composed of the
diﬀerential in (2)a n d( 3) along with their initial conditions.
One can easily show that the system has a conservation law
GUAadduct(t)
GUA0
= 1 −
1
GUA0
11 
i=4
yi(t). (4)
Since this equation holds for all times, it calculates, at least in
theory, the steady-state value of the unrepaired ratio.
3. Discussion
Numerousepidemiologicalstudieshaveimplicatedestrogens
in the development of breast cancer [1]. A pooled analysis
of nine prospective studies of serum estrogen levels and
breast cancer in over 2,400 postmenopausal women revealed
a strong association of serum E2 concentrations with breast
cancer risk [14]. In Figure 4(a), we show the results of
the combined model for a constant source of estrogen,
E2(t) ≡ 1, on the number of AP sites per 105 nucleotides
as well as the eﬀect of doubling the E2 level, E2(t) ≡ 2.
Clinical studies estimate that the doubling of serum E2 levels
confers a 1.3-fold increase in the risk of breast cancer [14].
Our model predicts a larger increase in the number of AP
sites, indicating the involvement of other factors, such as
enzyme activities. Enzymes involved in the production of6 Journal of Nucleic Acids
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Figure 5: Three-dimensional graph displaying the interaction
of estrogen exposure, enzyme genotypes, and resulting AP sites
per 105 nucleotides. We display estrogen exposure in tertiles on
the x-axis. Estrogen exposure can be represented by actual E2
values, measured in pmol/L, in combination with semiquantitative
estimates of each woman’s overall exposure to estrogen. The latter
can be derived by taking into account her total years of ovulation
as a function of current age, age at menarche, age at menopause,
numbers of full-term pregnancies, and the dosage and duration
of the use of exogenous estrogens. Thus, as far as the model is
concerned, exogenous and endogenous estrogens can be combined
althoughtheirprecisecontributiontoestrogenexposureispresently
unknown. The y-axis represents the combined eﬀects of wild-
type and variant enzyme haplotypes in the oxidative estrogen
metabolism and BER pathways on AP levels. In theory, all enzyme
genotype combinations shown in Figures 4(b) and 4(c) could be
plotted. However for clarity, we have plotted only the wild-type and
the lowest and highest variant haplotypes, separated into tertiles
based on their respective AP sites per 105 nucleotides, which is
represented on the z-axis. (The authors acknowledge Eric Parl for
the design of this ﬁgure.)
DNA-damaging carcinogens and in repair of the resulting
adducts are critical in maintaining the integrity of genomic
DNA. Genetic variants of these enzymes, which occur in the
generalpopulation,havebeenshowntoplayaroleinaltering
speciﬁc reactions catalyzed by the individual enzymes. For
example, we have shown that commonly occurring variants
of CYP1B1 diﬀer in their activity of producing 4-OHE2
from the parent hormone E2 [3, 15]. Similarly, the APE1
gene contains over 20 polymorphic sites, which have been
assessed functionally as recombinant proteins or based on
structural predictions [16, 17]. Several APE1 variants are
associated with substantially reduced or increased activities.
For example, L104R, E126D, and R237A exhibit 50% and
D283G 90% reduction in repair capacity [16]. In view of
these associations we used the model to examine the eﬀect
of variant enzyme haplotypes on the formation and repair
of DNA adducts. In Figure 4(b), we illustrate the eﬀect of
replacing wild-type CYP1B1 with a variant having a 30%
greater kcat and wild-type APE1 with a variant having a 30%
lower kcat. As expected, the more active CYP1B1 variant
increases DNA damage, and the less active APE1 variant
results in decreased repair, which is reﬂected in higher levels
of AP lesions for each. Their combined occurrence has an
additive eﬀect on AP lesions. Figure 4(c) shows the eﬀect
of diﬀerent variants of CYP1B1 and APE1, which cause a
decrease in number of AP sites relative to the wild-type
enzymes. The panels in Figure 4 demonstrate the number
the DNA adducts, which are constantly being created and
repaired as modeled in (2)a n d( 3), approaching steady
values in the integrated process of adduct formation and
repair.
A limitation of the model is its focus on BER and
the omission of other DNA repair pathways. While the
majority of adducts derived from 4-OHE2 and E2-3, 4-Q
are depurinating N7 guanine adducts susceptible to BER,
other stable, bulky DNA adducts that do not depurinate
are also formed. However, the level of the stable adducts
is three to four orders of magnitude lower than the level
of depurinating adducts justifying the emphasis on BER
[13, 18]. A vast number of depurination events occur under
normalconditionsinvolvingnotjustguaninebutotherbases
aswell[19].Theimportanceofdepurinatingadductsderived
from oxidative estrogen metabolism relative to the total
spectrum of depurination events is presently unknown.
Acriticalstrengthofthemodelisthatitcanreadilyincor-
porate additional enzymes involved in the metabolism, as
we have shown for CYP1A1, catechol-O-methyl transferase,
and glutathione S-transferase P1 in the estrogen metabolism
pathway [20]. Moreover, the model incorporates both phe-
notypic measures of estrogen exposure and genotypic data.
This is schematically shown in Figure 5, which displays the
interaction of estrogens, enzyme genotypes, and resulting
AP sites per 105 nucleotides as a three-dimensional graph.
In designing Figure 5, we assumed that the diﬀerence in
estrogen exposure between individual women is no more
than twofold, with the tertiles 1.0, 1.5, and 2.0 used for the x-
axis.Thisrangeisconservativesinceuptoﬁvefolddiﬀerences
in breast tissue concentrations have been reported in [21].
Regardless of the scale used for the x-axis, the production of
APsiteswouldbeexpectedtobegreaterinwomenwithmore
endogenous(moreovulatorycycles)orexogenous(hormone
replacement therapy, oral contraceptives) estrogen exposure.
The eﬀect of wild-type and variant enzyme haplotypes on
AP sites is displayed on the y-axis. It is evident from Figure 5
that the combined phenotypic and genotypic factors exert
not just an additive but multiplicative eﬀect on AP site levels,
which are shown on the z-axis.
In conclusion, we modeled the dynamic interaction
between the estrogen-mediated DNA damage pathway and
the DNA BER pathway in order to assess the overall
impact on carcinogenesis. The model encompasses a set of
diﬀerentialequationsrepresentingthesequenceofenzymatic
reactions in both damage and repair pathways. The model
allows us to examine the eﬀect of phenotypic and genotypic
factors such as diﬀerent concentrations of estrogen and
variant enzyme haplotypes on the formation and repair of
DNA adducts. As a practical application, the model can be
used to explore genetic factors in the damage-repair cycle
(through the rate constants and estrogen levels) as a ﬁrst
step in understanding why some women develop breast
cancer while others with similar circumstances do not. As
better information about the kinetics in the model (e.g.,
rate constants for diﬀerent haplotypes) becomes available,Journal of Nucleic Acids 7
predictions about breast cancer risk will improve. Thus, the
model may be useful for the construction of breast cancer
risk models.
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